A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice.

The aim of this study was to improve the potency of the currently used influenza subunit vaccines, which are of relatively low efficiency in high-risk groups. Influenza A virus (Shangdong/9/93) haemagglutinin/neuraminidase (H3N2), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) were encapsulated, each separately or combined, in multilamellar vesicles composed of dimyristoyl phosphatidylcholine. BALB/c mice were immunized once, i.p. or s.c., with 0.05-2.0 microg HN administered either as free antigen (F-HN), adsorbed to aluminum hydroxide (Al-HN), or encapsulated in liposomes (Lip-HN), separately or together with 1 x 10(2)-4.5 x 10(4) units of free or encapsulated cytokines. Serum antibodies were assayed on days 11-360 by the haemagglutination-inhibition (HI) test and ELISA. Protective immunity against intranasal virus challenge was determined at 9-14 months post-vaccination. The following results were obtained: (1) The efficiency of encapsulation in liposomes was 95, 90 and 38% for HN, IL-2 and GM-CSF, respectively, and the liposomal preparations were highly stable as an aqueous dispersion for > 2 months at 4 degrees C. (2) Following immunization with 0.5 microg Lip-HN, there was an earlier, up to 50-fold stronger, and 3-5 times longer response than that obtained with nonliposomal HN. (3) Coimmunization with free cytokines further increased the response 2-20 times and the two cytokines had an additive effect. (4) Liposomal cytokines were 2-20 times more effective than the free cytokines and their stimulatory effect was more durable. (5) A 100% seroconversion (HI titer > or = 40) was achieved with only 10-25% of the routinely used antigen dose, by encapsulating either antigen or cytokine. (6) The level of protection following vaccination with the combined liposomal vaccines was 70-100% versus 0-25% in mice immunized with Al-HN alone, and no toxicity was observed. In conclusion, our animal experiments show that the liposomal vaccines are superior to the currently used influenza vaccines, increasing the response by 2-3 orders of magnitude in mice. This approach may also prove valuable for subunit vaccines against other microorganisms.

[1]  Gregory Gregoriadis,et al.  Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes , 1984, Bio/Technology.

[2]  L. Thibodeau,et al.  Mouse response to influenza immunosomes. , 1985, Vaccine.

[3]  G. Gregoriadis,et al.  Effect of interleukin-2 on the immunoadjuvant action of liposomes , 1989 .

[4]  P. Anderson,et al.  Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. , 1994, Cytokine.

[5]  M. Guillaume,et al.  Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. , 1996, Vaccine.

[6]  A. Breckenridge.  Hypertension and hyperuricaemia. , 1966, Lancet.

[7]  R. Rubin,et al.  Cytokines as potential vaccine adjuvants , 1994, Biotherapy.

[8]  M. Manning,et al.  Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. , 1995, The Journal of infectious diseases.

[9]  J. Bamburg,et al.  A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. , 1990, Analytical biochemistry.

[10]  G. Gregoriadis.  Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. , 1994, ImmunoMethods.

[11]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[12]  Y. Barenholz,et al.  Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. , 1997, Journal of immunotherapy.

[13]  N. Van Rooijen,et al.  MUCOSAL IMMUNOADJUVANT ACTIVITY OF LIPOSOMES: ROLE OF ALVEOLAR MACROPHAGES , 1996, Immunology.

[14]  S. Cryz,et al.  Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. , 1997, Vaccine.

[15]  D. Engelhard,et al.  Antibody response to influenza immunization in patients after heart transplantation. , 1997, Vaccine.

[16]  S. Sencer,et al.  Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma. , 1991, European cytokine network.

[17]  G. Gregoriadis,et al.  Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. , 1997, Immunology letters.

[18]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[19]  J. Löwer,et al.  Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. , 1995, Vaccine.

[20]  D. Fuller,et al.  Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization , 1996 .

[21]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[22]  P. Pietrobon,et al.  Liposome design and vaccine development. , 1995, Pharmaceutical biotechnology.

[23]  J. Imanishi,et al.  Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. , 1992, Vaccine.

[24]  P. Wyde,et al.  Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. , 1990, Vaccine.

[25]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines , 1996 .

[26]  T. Merigan,et al.  Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. , 1992, Vaccine.

[27]  S. Meuer,et al.  LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION , 1989, The Lancet.

[28]  C. Bucana,et al.  Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. , 1995, AIDS research and human retroviruses.

[29]  M. Provinciali,et al.  Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects , 1994, Mechanisms of Ageing and Development.

[30]  H. Danenberg,et al.  Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. , 1995, Vaccine.

[31]  D. Crommelin,et al.  Liposomes and ISCOMS as vaccine formulations. , 1995, Biochimica et biophysica acta.

[32]  R. Chanock,et al.  Influenza A and B virus infection in infants and young children during the years 1957-1976. , 1979, American journal of epidemiology.

[33]  S. Muller,et al.  Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes. , 1994, Vaccine.

[34]  Heath Aw.  Cytokines as immunological adjuvants. , 1995 .

[35]  J. Mullooly,et al.  Impact of epidemic type A influenza in a defined adult population. , 1980, American journal of epidemiology.

[36]  G. Gregoriadis.  Liposomes as drug carriers : recent trends and progress , 1988 .

[37]  Gregory Gregoriadis,et al.  Liposomes As Immunological Adjuvants and Vaccine Carriers , 1996 .

[38]  R. Mannino,et al.  Intranasal immunization with proteoliposomes protects against influenza. , 1989, Vaccine.

[39]  Y. Barenholz,et al.  Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects. , 1995, Cancer biotherapy.

[40]  Y. Barenholz,et al.  Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. , 1997, Vaccine.

[41]  Y. Barenholz,et al.  Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[42]  P. Tarr,et al.  Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  V. Carreño,et al.  Recombinant γ‐interferon as adjuvant to hepatitis B vaccine in hemodialysis patients , 1990 .

[44]  R. Ho,et al.  Application of Liposomes in Antigen Presentation and Cytokine Delivery , 1996 .

[45]  G. Gregoriadis,et al.  Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen. , 1992, Vaccine.

[46]  M. Marinaro,et al.  Oral but Not Parenteral Interleukin (IL)-12 Redirects T Helper 2 (Th2)-type Responses to an Oral Vaccine Without Altering Mucosal IgA Responses , 1997, The Journal of experimental medicine.

[47]  S. Segev,et al.  Failure of influenza vaccination in the aged , 1988, Journal of medical virology.

[48]  A. Duits,et al.  Immunoadjuvant activity of a liposomal IL-6 formulation. , 1993, Vaccine.

[49]  L. Babiuk,et al.  Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. , 1997, Vaccine.

[50]  E. Abraham,et al.  Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. , 1992, Journal of immunology.

[51]  D. Crommelin,et al.  LIPOSOME-BASED CANCER VACCINES , 1996 .

[52]  J. Wilschut,et al.  Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. , 1995, Vaccine.

[53]  Y. Barenholz,et al.  A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. , 1999, Vaccine.